Abstract
Giriş: Resolvin molekülleri, inflamatuar barsak hastalıklarında (İBH) anti-İnflamatuar aktiviteye sahiptir. Çalışmamızda serum resolvin D1 (RvD1) ve resolvin E1 (RvE1) düzeylerinin İBH’da klinik ve laboratuvar özellikler ile korelasyon gösterip göstermediğini değerlendirilmesi planlanmıştır.
Yöntemler: Bu vaka-kontrol çalışmasına İBH’'lı 62 hasta [32 ülseratif kolit (ÜK), 30 Crohn hastalığı (CH) bulunan vaka] ve 28 sağlıklı kontrol dahil edildi. ÜK hastalarının klinik ve endoskopik özellikleri Mayo Klinik Skorlama (MKS) sistemine göre CH vakalarının klinik aktivitesi ise Crohn Hastalık Aktivite İndeksine (CHAİ) göre kaydedildi. Serum RvD1 ve RvE1 ölçümü için insan RvD1 ve RvE1 enzim bağımlı immunosorbent testi (ELISA) kitleri kullanılmıştır.
Bulgular: Serum RvD1 konsantrasyonları ÜK ve CH’da sağlıklı kontrollere göre anlamlı olarak düşük bulundu [182,69 (118,24- 450,80) ng/L ve 342,07 (203,57-989,04) ng/L ve 353,65 (216,14- 1125,40) ng/L, sırasıyla, p= 0.002]. RvD1 ve RvE1 konsantrasyonları, klinik olarak remisyon fazında olan ÜK hastalarında aktivasyon fazında olanlara göre daha yüksekti [602,18 (176,13-1181,60) ng/L ve 170,37 (113,21-216,21) ng/L, p=0,005-302,10 (122,18-527,37) ng/L ve 74,17 (67,38-122,66) ng/L, sırasıyla, p=0,004]. RvD1 değerleri inaktif endoskopik bulgusu olan ÜK’li hastalarda aktif hastalığı olanlara göre daha yüksekti [ 426,11 (175,94-891,03) ng/L ve 169,62(109,97-202,80) ng/L, sırasıyla p=0,009]. ROC (receiver operating characteristic curve) analizi serum RvD1 ve RvE1 düzeylerinin, ÜK'de artan Mayo klinik skorları yönünden tanısal değerinin bulunduğunu göstermiştir (AUC=0.809, 95% CI: 0.630- 0.988, p<0.001 ve AUC=0.814, 95%CI: 0.637-0.991, sırasıyla, p<0.001).
Sonuç: Azalmış serum RvD1 değerleri, ÜK hastalığının teşhisi ve hastalık aktivitesinin değerlendirilmesinde yardımcı bir biyobelirteç olarak kullanılabilir.
Keywords
References
- 1. Osterman M. T, Lichtenstein G. R. Ulcerative Colitis. In: Feldman M, Friedman SL. Brandt JL. (Eds). Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Philadelphia:Elselvier Saunders;Volume 2; 2016:2023-61.
- 2. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest. 2018; 128:2657-69.
- 3. Abdolmaleki F, Kovanen PT, Mardani R, Gheibi-Hayat SM, Bo S, Sahebkar A. Resolvins: Emerging Players in Autoimmune and Inflammatory Diseases. Clin Rev Allergy Immunol. 2020; 58:82-91.
- 4. Serhan CN, Brain SD, Buckley CD, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2007; 21:325-32.
- 5. Schwab JM, Serhan CN. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol. 2006; 6:414-20.
- 6. Dalli J, Winkler JW, Colas RA, et al. Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol. 2013;20: 188-201.
- 7. Abdolmaleki F, Farahani N, Gheibi Hayat SM, et al. The Role of Efferocytosis in Autoimmune Diseases. Front Immunol. 2018;(9):1645.
- 8. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev. 2011; 111:5922-43.
- 9. Das UN. Inflammatory bowel disease as a disorder of an imbalance between pro- and anti-inflammatory molecules and deficiency of resolution bioactive lipids. Lipids Health Dis. 2016 Jan 13; 15:11.
- 10. Karatay E, Utku ÖG. Serum resolvin D1 levels as a marker of inflammation in constipation dominant irritable bowel syndrome. Turkish J Gastroenterol. 2020; 31:113-19.
- 11. Molaei E, Molaei A, Hayes AW, Karimi G. Resolvin D1, therapeutic target in acute respiratory distress syndrome. Eur J Pharmacol. 2021 Nov 15; 911:174527.
- 12. Dartt DA, Hodges RR, Serhan CN. Immunoresolvent Resolvin D1 Maintains the Health of the Ocular Surface. Adv Exp Med Biol. 2019; 1161:13-25.
- 13. Cheng T, Ding S, Liu S, Li X, Tang X, Sun L. Resolvin D1 Improves the Treg/Th17 Imbalance in Systemic Lupus Erythematosus Through miR-30e-5p. Front Immunol. 2021; 12:668760.
- 14. Salas-Hernández A, Espinoza-Pérez C, Vivar R, et al. Resolvin D1 and E1 promote resolution of inflammation in rat cardiac fibroblast in vitro. Mol. Biol. Rep. 2021; 48:57-66.
- 15. Quiros M, Feier D, Birkl D, Agarwal R, Zhou DW, García AJ, et al. Resolvin E1 is a pro-repair molecule that promotes intestinal epithelial wound healing. Proc. Natl. Acad. Sci. U S A. 2020; 117:9477-82.
- 16. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Eng. J Med. 1987; 317:1625-29.
- 17. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70:439-44.
- 18. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. Hepatol. 2005; 19: 5A-36A.
- 19. Mangino MJ, Brounts L, Harms B, Heise C. Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat. 2006; 79:84-92.
- 20. Weylandt KH, Kang JX, Wiedenmann B, Baumgart DC. Lipoxins and resolvins in inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13:797-99.
- 21. Kuzumoto T, Tanigawa T, Higashimori A, et al. Protective role of resolvin D1, a pro-resolving lipid mediator, in nonsteroidal anti-inflammatory drug-induced small intestinal damage. PLoS One. 2021;16:e0250862.
- 22. Yang M, Song XQ, Han M, Liu H. The role of Resolvin D1 in liver diseases. Prostaglandins Other Lipid Mediat. 2022; 160:106634.
- 23. Zhong X, Lee HN, Surh YJ. RvD1 inhibits TNFα-induced c-Myc expression in normal intestinal epithelial cells and destabilizes hyper-expressed c-Myc in colon cancer cells. Biochem. Biophys. Res. Commun. 2018; 496:316-23.
- 24. Seki H, Tani Y, Arita M. Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1. Prostaglandins Other Lipid Mediat. 2009; 89:126-30.
- 25. Günay S, Taşova F, Yılmaz HE, Paköz ZB, Çekiç C. Serum Resolvin E1 Levels and Its Relationship with Disease Activity in Ulcerative Colitis. Gastroenterol. Res. Pract. 2019; 2019:6258327.
- 26. Kikut J, Drozd A, Mokrzycka M, Grzybowska-Chlebowczyk U, Ziętek M, Szczuko M. Are EPA and DHA Derivatives Involved in IBD Remission? J Clin Med. 2022; 11:2388.
- 27. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011; 474:298-306.
- 28. Magro F, Gionchetti P, Eliakim R, et al. “Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extraintestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders,” Journal of Crohn's & Colitis, 2017;11:649-70.
- 29. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010; 7:15-29.
Abstract
Introduction: Resolvin molecules have anti-inflammatory activity in inflammatory bowel diseases (IBDs). We aimed to evaluate whether serum resolvin D1 (RvD1) and resolvin E1 (RvE1) values can correlate to clinical and laboratory traits of IBDs.
Methods: This case-control study included 62 patients with IBDs (32 ulcerative colitis (UC) patients, 30 Crohn’s disease (CD) patients) and 28 healthy controls. The Mayo Clinical scoring system (MCS) was used for the clinical and endoscopic features for UC, and the Crohn's disease activity index was used to assess the disease activity in CD patients. Human RvD1 and RvE1 kits were used for the serum enzyme-linked immunosorbent assay.
Results: RvD1 concentrations were significantly lower in UC and CD patients compared to the control group [182.69 (118.24-450.80) ng/L and 342.07 (203.57-989.04) ng/L vs. 353.65 (216.14-1125.40) ng/L respectively, p=0.002]. RvD1 and RvE1 concentrations were higher in UC patients who were in the clinically remission phase than the patients in the activation phase [602.18 (176.13-1181.60) ng/L and 170.37 (113.21-216.21) ng/L, p=0.005 vs. 302.10 (122.18-527.37) ng/L and 74.17 (67.38-122.66) ng/L, p=0.004, respectively]. RvD1 values were higher in UC patients who had inactive endoscopic findings than the patients having active disease [426.11(175.94- 891.03 ng/L and 169.62(109.97-202.80) ng/L, p=0.009, respectively]. The ROC (receiver operating characteristic curve) analysis revealed RvD1 and RvE1 levels had considerable diagnostic significances for the increased MCS in UC (AUC=0.809, 95%CI: 0.630-0.988, p<0.001 vs AUC=0.814, 95%CI: 0.637-0.991, p<0.001).
Conclusion: Decreased serum RvD1 values might be used as an auxiliary biomarker for the diagnosis and the activity of UC.
References
- 1. Osterman M. T, Lichtenstein G. R. Ulcerative Colitis. In: Feldman M, Friedman SL. Brandt JL. (Eds). Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Philadelphia:Elselvier Saunders;Volume 2; 2016:2023-61.
- 2. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest. 2018; 128:2657-69.
- 3. Abdolmaleki F, Kovanen PT, Mardani R, Gheibi-Hayat SM, Bo S, Sahebkar A. Resolvins: Emerging Players in Autoimmune and Inflammatory Diseases. Clin Rev Allergy Immunol. 2020; 58:82-91.
- 4. Serhan CN, Brain SD, Buckley CD, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2007; 21:325-32.
- 5. Schwab JM, Serhan CN. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol. 2006; 6:414-20.
- 6. Dalli J, Winkler JW, Colas RA, et al. Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol. 2013;20: 188-201.
- 7. Abdolmaleki F, Farahani N, Gheibi Hayat SM, et al. The Role of Efferocytosis in Autoimmune Diseases. Front Immunol. 2018;(9):1645.
- 8. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev. 2011; 111:5922-43.
- 9. Das UN. Inflammatory bowel disease as a disorder of an imbalance between pro- and anti-inflammatory molecules and deficiency of resolution bioactive lipids. Lipids Health Dis. 2016 Jan 13; 15:11.
- 10. Karatay E, Utku ÖG. Serum resolvin D1 levels as a marker of inflammation in constipation dominant irritable bowel syndrome. Turkish J Gastroenterol. 2020; 31:113-19.
- 11. Molaei E, Molaei A, Hayes AW, Karimi G. Resolvin D1, therapeutic target in acute respiratory distress syndrome. Eur J Pharmacol. 2021 Nov 15; 911:174527.
- 12. Dartt DA, Hodges RR, Serhan CN. Immunoresolvent Resolvin D1 Maintains the Health of the Ocular Surface. Adv Exp Med Biol. 2019; 1161:13-25.
- 13. Cheng T, Ding S, Liu S, Li X, Tang X, Sun L. Resolvin D1 Improves the Treg/Th17 Imbalance in Systemic Lupus Erythematosus Through miR-30e-5p. Front Immunol. 2021; 12:668760.
- 14. Salas-Hernández A, Espinoza-Pérez C, Vivar R, et al. Resolvin D1 and E1 promote resolution of inflammation in rat cardiac fibroblast in vitro. Mol. Biol. Rep. 2021; 48:57-66.
- 15. Quiros M, Feier D, Birkl D, Agarwal R, Zhou DW, García AJ, et al. Resolvin E1 is a pro-repair molecule that promotes intestinal epithelial wound healing. Proc. Natl. Acad. Sci. U S A. 2020; 117:9477-82.
- 16. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Eng. J Med. 1987; 317:1625-29.
- 17. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70:439-44.
- 18. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. Hepatol. 2005; 19: 5A-36A.
- 19. Mangino MJ, Brounts L, Harms B, Heise C. Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat. 2006; 79:84-92.
- 20. Weylandt KH, Kang JX, Wiedenmann B, Baumgart DC. Lipoxins and resolvins in inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13:797-99.
- 21. Kuzumoto T, Tanigawa T, Higashimori A, et al. Protective role of resolvin D1, a pro-resolving lipid mediator, in nonsteroidal anti-inflammatory drug-induced small intestinal damage. PLoS One. 2021;16:e0250862.
- 22. Yang M, Song XQ, Han M, Liu H. The role of Resolvin D1 in liver diseases. Prostaglandins Other Lipid Mediat. 2022; 160:106634.
- 23. Zhong X, Lee HN, Surh YJ. RvD1 inhibits TNFα-induced c-Myc expression in normal intestinal epithelial cells and destabilizes hyper-expressed c-Myc in colon cancer cells. Biochem. Biophys. Res. Commun. 2018; 496:316-23.
- 24. Seki H, Tani Y, Arita M. Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1. Prostaglandins Other Lipid Mediat. 2009; 89:126-30.
- 25. Günay S, Taşova F, Yılmaz HE, Paköz ZB, Çekiç C. Serum Resolvin E1 Levels and Its Relationship with Disease Activity in Ulcerative Colitis. Gastroenterol. Res. Pract. 2019; 2019:6258327.
- 26. Kikut J, Drozd A, Mokrzycka M, Grzybowska-Chlebowczyk U, Ziętek M, Szczuko M. Are EPA and DHA Derivatives Involved in IBD Remission? J Clin Med. 2022; 11:2388.
- 27. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011; 474:298-306.
- 28. Magro F, Gionchetti P, Eliakim R, et al. “Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extraintestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders,” Journal of Crohn's & Colitis, 2017;11:649-70.
- 29. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010; 7:15-29.
Details
| Primary Language | English |
|---|---|
| Subjects | Gastroenterology and Hepatology |
| Journal Section | Research Articles |
| Authors | |
| Early Pub Date | October 16, 2023 |
| Publication Date | October 16, 2023 |
| Published in Issue | Year 2023 Volume: 4 Issue: Ek Sayı |
Cite
